

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMIBUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

12th November, 2021

To,
The Corporate Relations Department,
Bombay Stock Exchange Limited,
P. J. Tower, Dalal Street, Fort,
Mumbai- 400 001.

Ref: Scrip Code: 524516

Outcome of Board Meeting

Dear Sir/ Madam,

We are pleased to inform the Stock Exchange that the Board of Directors M/s Bacil Pharma Limited at their meeting held on 12th November, 2021, through video conferencing has considered and approved the following:

- The Unaudited Financial Results along with statement of Assets and Liabilities and Cash flow for the Quarter and half year ended on 30th September, 2021.
- The Limited Review Report for the Quarter and half year ended on 30th September, 2021.
- Other routine Business with the permission of the Chair.

Please note that the Meeting of the Board of Directors commenced at 05.00 P. M. and concluded at 05:15 P. M.

Kindly acknowledge the receipt of the same.

For Bacil Pharma Limited


Prakash Shah
Director
DIN: 01136800



BACIL PHARMA LIMITED
CIN : {L24200MH1987PLC043427}

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021

(Amount in Lakhs)


Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-	-	-
	Other income	1.66	1.69	2.40	3.35	4.07	7.39
	Total revenue	1.66	1.69	2.40	3.35	4.07	7.39
2	Expenses						
	Employee benefits expense	1.31	1.35	0.71	2.66	1.22	5.22
	Depreciation and amortization expense	0.09	0.09	0.12	0.19	0.25	0.49
	Other expenses	8.05	2.61	2.29	10.66	3.93	25.64
	Total expenses	9.45	4.06	3.12	13.51	5.40	31.36
3	Profit/(Loss) before Exceptional Items & Tax	(7.79)	(2.37)	(0.71)	(10.15)	(1.33)	(23.97)
4	Tax expense:						
	Current tax	-	-	-	-	-	-
	Deferred tax	0.02	0.01	0.01	0.03	0.02	0.04
5	Profit/(Loss) from ordinary activities after tax	(7.76)	(2.36)	(0.70)	(10.12)	(1.31)	(23.92)
6	Other Comprehensive Income (OCI)						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	4.89	8.26	1.55	13.15	17.47	33.21
	Income tax relating to these items	(1.27)	(2.15)	(0.40)	(3.42)	(4.73)	(8.82)
	Total Other Comprehensive Income (OCI)	3.62	6.11	1.14	9.73	12.74	24.39
	Profit/(Loss) for the Period	(4.15)	3.75	0.44	(0.39)	11.44	0.47
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589	589	589	589	589	589
7	Earning Per Share (EPS) (Not annualised)						
	Basic	(0.13)	(0.04)	(0.01)	(0.17)	(0.02)	(0.41)
	Diluted	(0.13)	(0.04)	(0.01)	(0.17)	(0.02)	(0.41)

Notes:

- The Above Financial Results were reviewed by the audit committee and approved by the Board of Directors of the company at their Meeting held on 12/11/2021. The Statutory auditor have expressed an unmodified opinion.
- The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- The statutory Auditors of the company have carried out the limited review.
- The company has no separate reportable segment.
- Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

For BACIL PHARMA LTD.

Prakash Shah
Director
DIN: 01136800
Place: Mumbai
Dated: 12/11/2021



BACIL PHARMA LIMITED.
CIN : {L24200MH1987PLC043427}
Statement of Asset and Liabilities

(Amount in Lakhs)

	As on 30.09.2021 (Unaudited)	As on 31.03.2021 (Audited)
<u>Assets</u>		
Non-Current Asset		
Property, plants and Equipment	1.28	1.46
Assets Classified as held for sale	229.00	250.00
Financial Assets		
1. Investments	24.62	23.56
2. Loans	96.19	92.83
Deferred Tax Assets	7.37	10.75
Total Non-current Assets (A)	358.46	378.61
Current Assets		
Inventories		
Financial Assets		
1. Investments	19.11	13.88
2. Cash and Cash Equivalent	9.45	9.90
3. Other current Assets	6.51	6.43
Total Current Assets (B)	35.07	30.22
Total Assets (A+B)	393.53	408.83
Equities and Liabilities		
<u>Equity</u>		
Equity Share Capital	652.72	652.72
Other Equity	(513.97)	(513.58)
Total Equity (A)	138.74	139.13
<u>Liabilities</u>		
Current Liabilities		
Financial Liabilities		
1. Trade Payable	2.14	1.12
2. Borrowings	20.56	17.56
3. Other Financial Liabilities	225.22	250.00
Other Current Liabilities	3.77	0.11
Provisions	3.10	0.91
Total current Liabilities (B)	254.79	269.70
Total Equities and Liabilities (A+B)	393.53	408.83

For BACIL PHARMA LTD.

Prakash Shah
Director
DIN: 01136800
Place: Mumbai
Dated: 12/11/2021



Notes:

2. Disclosure of standalone cashflow as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2021

(Amount in Lakhs)

Particulars	Half Year	Year ended
	30.9.2021 (Reviewed)	31.3.2021 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	(10.15)	(23.97)
Adjustments for		
Depreciation	0.19	0.49
Loss on sale of Investments	6.08	-
Interest & Dividend Income	(3.35)	(14.18)
Operating profit before working capital changes	(7.24)	(37.65)
Working capital adjustments :-		
Increase / (Decrease) in Trade and Other Payables	1.02	(2.43)
Increase / (Decrease) in Borrowings	3.00	0.68
Increase / (Decrease) in Provisions	2.19	(0.32)
Increase / (Decrease) in Other Current Liabilities	3.66	(0.08)
(Increase) / Decrease in Other Current Assets	(3.86)	(0.00)
Cash generated from / (used in) operations	6.01	(39.81)
Direct taxes paid (Net of Refunds)		
Net cash (used in) / from generated from operating activities	(1.23)	(39.81)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Proceeds Purchase/ Sale of investments	0.78	38.60
Interest & Dividend Income	3.35	14.18
Net cash (used in) / generated from investing activities	4.13	52.78
C. CASH FLOW FROM FINANCING ACTIVITIES		
(Increase)/ Decrease of Loans and Advances	(3.36)	(7.33)
Net cash (used in) / generated from financing activities	(3.36)	(7.33)
D. Net decrease in cash and cash equivalents (A+B+C)	(0.45)	5.64
Cash and cash equivalents at the beginning of the year	9.90	4.26
Cash and cash equivalents at the end of the year	9.45	9.90

For BACIL PHARMA LTD.

Prakash Shah

Director

DIN: 01136800

Place: Mumbai

Dated: 12/11/2021



Independent Auditor's Review Report on the Quarterly and Half Year Ended Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors

BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the quarter and half year ended September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Emphasis of Matter

Advance given to creditors and outstanding trade payables/ receivables which pertains to the business of the company that was closed in FY 2018-19, are yet to be settled. Due to the outbreak of Corona Virus (Covid 19) and lockdown on the account of the same the recoverability of the balances is yet to be determined by the management. These receivables are subject to confirmation by management.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Laxmikant Kabra & Co LLP

Chartered Accountants

Firm Reg. No.: 117183W/ W100736

L.K. Kabra

CA Laxmikant Kabra

Partner

Membership No.: 101839



Place: Thane

Date: 12th November 2021

UDIN: 21101839AAAAHZ3171